Click Here to
News, Updates,
& More
Stay Up
to Date

MURANO: Venetoclax-Rituximab at Fixed Duration Beats Chemo­immunotherapy in Relapsed/Refractory CLL

JHOP - March 2019 Vol 9, No 1 - ASH
Download PDF
Phoebe Starr

A 2-year duration of combination immunotherapy with ven­etoclax and rituximab improved survival compared with standard-of-care chemoimmunotherapy combination with bendamustine plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), according to follow-up data from the MURANO clinical trial presented at ASH 2018. Early results were first presented at ASH 2017.

Fixed-duration venetoclax plus rituximab achieved minimal residual disease (MRD)-negative status in 78% of patients. At a median follow-up of 3.3 years, the 6-month estimated progression-free survival (PFS) was 92% among 130 patients who completed 2 years of venetoclax therapy and remained off therapy for a median of 9.9 months. At 12 months, the estimated PFS was 87%. The estimated 3-year overall survival was 87.9% with venetoclax plus rituximab versus 79.5% with bendamustine plus rituximab.

“Venetoclax-rituximab is a chemotherapy-free option with a fixed treatment duration that can potentially provide prolonged progression-free survival, along with minimal residual disease negativity, in patients with relapsed or refractory CLL,” said lead investigator John F. Seymour, MBBS, PhD, FRACP, Director, Department of Haematology, Peter MacCallum Cancer Centre & the Royal Melbourne Hospital, Australia.

“This analysis shows that a high proportion of patients treated with venetoclax/rituximab maintained minimal residual disease negativity and progression-free survival after completing the fixed treatment duration,” Dr Seymour said. “The survival benefits are clinically meaningful, and minimal residual disease status at cessation of therapy is a strong predictor of durable progression-free survival off the drug. These findings establish the feasibility and support the use of fixed-duration venet­oclax-rituximab for all patients with relapsed or refractory CLL.”

MURANO: Additional 12-Month Results

The first results from the MURANO study were presented at ASH 2017. The results presented at ASH 2018 provided evidence from an additional 12 months of follow-up. MURANO was conducted at 109 sites across 20 countries and enrolled 389 patients with relapsed or refractory CLL who were randomized in a 1:1 ratio to (1) fixed-duration venetoclax and rituximab for 6 cycles, followed by venetoclax alone once daily for a total of 2 years or to (2) 6 cycles of bendamustine plus rituximab. The current standard practice for relapsed or refractory CLL is venetoclax therapy alone until the disease progresses.

At baseline, the median age of the MURANO participants was 65 years, and the median number of previous therapies was 1. For the first results presented at ASH 2017, at a median follow-up of 23.8 months, the median PFS was not reached in the venetoclax plus rituximab arm versus PFS of 17 months with bendamustine and rituximab (P <.0001). With another 1 year of follow-up, of 130 patients who reached cessation of venetoclax therapy without progressive disease, the estimated 3-year PFS was 71% for those in the venetoclax plus rituximab arm versus 15% in the bendamustine plus rituximab arm.

“The magnitude of effect was comparable in all biologic subtypes, regardless of TP53 [mutation] or 17p deletion,” Dr Seymour said.

No new safety events emerged dur­ing the trial for any of the agents. During the single-agent venetoclax treatment phase, 10% of patients had an adverse event that led to drug withdrawal, 4% needed dose reductions, and 26% of patients required dose interruptions. Fatal events were reported in 4% of patients.

Grade 3 or 4 adverse events were reported in 35% of patients in the venetoclax plus rituximab arm during the single-agent venetoclax period. Grade 3 or 4 infections were reported in 7% of patients during the single-agent phase. The number of cases of Richter’s transformation was similar in each arm: 7 with the immuno­therapy combination and 6 with chemo­immunotherapy.

MRD negativity was reported in 78% of patients who completed the 2-year course of venetoclax treatment without disease progression. Among 83 patients with MRD-negative status, only 2 patients had disease progression. “MRD-negativity correlated with disease progression,” Dr Seymour told attendees. “MRD is the strongest predictor for progression events. Other risk factors did not predict disease recurrence.”

Related Items
FDA Unveils Pilot Program to Expand Access to Investigational Oncology Drugs
Phoebe Starr
Web Exclusives published on July 29, 2019 in ASCO
Checkpoint Inhibition Consolidation Therapy Promising in High-Risk Hematologic Malignancies
Charles Bankhead
JHOP - March 2019 Vol 9, No 1 published on March 13, 2019 in ASH
Researchers Identify First Mutation to Explain Resistance to Venetoclax
Phoebe Starr
JHOP - March 2019 Vol 9, No 1 published on March 13, 2019 in ASH
Checkpoint Inhibitor a New Approach to Jump-Start a Waning Response to CAR T-Cell Therapy
Phoebe Starr
JHOP - March 2019 Vol 9, No 1 published on March 13, 2019 in Immunotherapy, ASH
Durable Responses to CAR T-Cell Therapy in B-Cell Lymphomas
Phoebe Starr
JHOP - March 2019 Vol 9, No 1 published on March 13, 2019 in Lymphoma, ASH
First-Line Ibrutinib Improves Outcomes Compared with Current Standard of Care in Older Patients with CLL
Wayne Kuznar
JHOP - March 2019 Vol 9, No 1 published on March 13, 2019 in Leukemia, ASH
Explosive Development of BCMA CAR T-Cell Therapy for Multiple Myeloma
Phoebe Starr
Web Exclusives published on March 6, 2019 in Immunotherapy, Multiple Myeloma
Brigatinib, Next-Generation ALK Inhibitor, Improves Survival versus Crizotinib in Patients with NSCLC and ALK Mutation
Phoebe Starr
Web Exclusives published on February 20, 2019 in Lung Cancer
5 mg Tamoxifen as Effective as 20 mg Daily in Early Localized Breast Cancer
Phoebe Starr
Web Exclusives published on January 28, 2019 in Breast Cancer
TLR9 Agonist plus Immunotherapy May Overcome Resistance to PD-1 Inhibition
Phoebe Starr
Web Exclusives published on November 20, 2018 in Emerging Therapies
Last modified: March 14, 2019